{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:19:58Z","timestamp":1792819198729,"version":"4.5.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"No funding","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Prostate cancer is the most commonly diagnosed cancer among men in 112 countries, accounting for approximately 15% of all cancer cases. Whilst the 5-year survival rate for localised disease exceeds 90%, there is a significant drop to 50% if metastases are present. Following the VISION and TheraP trials,\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-therapy was approved for treatment of metastatic castrate resistant prostate cancer by the FDA and EMA 2022. Patient selection for\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-therapy is now relatively well defined, guided by PSMA-PET\/CT criteria established in pivotal trials. Nevertheless, clinical consensus on appropriate criteria is still evolving, and additional imaging modalities such as\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG\u00a0PET, post-therapy SPECT\/CT, or emerging techniques such as whole-body diffusion-weighted MRI may serve as valuable adjuncts to identify PSMA-negative or treatment-resistant disease that may not be apparent on PSMA-PET\/CT alone. This review examines the current evidence on imaging biomarkers and complementary diagnostic techniques used for patient selection, treatment monitoring, and response assessment in [\u00b9\u2077\u2077Lu]Lu-PSMA-617 therapy for metastatic castrate resistant prostate cancer. Baseline imaging biomarkers on PSMA-PET\/CT, such as mean standardised uptake value (SUV\n                      <jats:sub>mean<\/jats:sub>\n                      ), PSMA-avid total tumour volume, and inter-lesional PSMA heterogeneity, have shown promise in predicting treatment response and assessing outcomes. Additionally, statistical prognostic models have been developed to predict treatment efficacy, though further validation is required. Imaging plays a crucial role and should be considered alongside blood biomarkers, clinic-demographic history, and circulating tumour markers to improve patient selection for\n                      <jats:sup>177<\/jats:sup>\n                      Lu-PSMA-therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>PSMA-PET\/CT is the established imaging modality for patient selection for \u00b9\u2077\u2077Lu-PSMA-therapy, while \u00b9\u2078F-FDG PET, post-therapy SPECT\/CT, and emerging techniques such as whole-body diffusion-weighted MRI can be adjunctive for patient selection, response assessment and long-term monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            PSMA-PET\/CT is the mainstay for patient selection for \u00b9\u2077\u2077Lu-PSMA-therapy.\n                            <jats:sup>18<\/jats:sup>\n                            F-FDG PET, SPECT\/CT or whole-body diffusion-weighted MRI could be used as adjuncts.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Interim and longitudinal PSMA-PET\/CT offer sensitive detection of progression, quantitative biomarkers for response assessment, and standardised frameworks.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Advances in AI, radiomics, and standardisation frameworks may refine prognostication, enable personalised dosimetry, and integrate imaging biomarkers into clinical practice, though further validation is required.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-025-02151-x","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:12:08Z","timestamp":1768558328000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of multimodality imaging in selection, response assessment, and follow-up of patients receiving 177Lutetium-PSMA-therapy"],"prefix":"10.1186","volume":"17","author":[{"given":"Aditi","family":"Ranjan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minal","family":"Padden-Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Abdel-Aty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Galante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzra","family":"Maricar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetokunbo","family":"Adesina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraj","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9781-973X","authenticated-orcid":false,"given":"Sola","family":"Adeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2151_CR1","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1080\/14737140.2023.2213892","volume":"23","author":"K Patell","year":"2023","unstructured":"Patell K, Kurian M, Garcia JA, Mendiratta P, Barata PC, Jia AY (2023) Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review. Expert Rev Anticancer Ther 23:731\u2013744","journal-title":"Expert Rev Anticancer Ther"},{"key":"2151_CR2","unstructured":"Office for National Statistics (2019) Cancer survival in England\u2014adults diagnosed. Available via https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/conditionsanddiseases\/datasets\/cancersurvivalratescancersurvivalinenglandadultsdiagnosed"},{"key":"2151_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1053\/j.seminoncol.2023.09.003","volume":"51","author":"O Longoria","year":"2024","unstructured":"Longoria O, Beije N, de Bono JS (2024) PARP inhibitors for prostate cancer. Semin Oncol 51:25\u201335","journal-title":"Semin Oncol"},{"key":"2151_CR4","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1007\/s00259-017-3895-x","volume":"45","author":"FE von Eyben","year":"2018","unstructured":"von Eyben FE, Roviello G, Kiljunen T et al (2018) Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 45:496\u2013508","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, Jd B, Chi KN, Fizazi K, Herrmann K, Rahbar K (2021) Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385:1091\u20131103","journal-title":"N Engl J Med"},{"key":"2151_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797\u2013804","journal-title":"Lancet"},{"key":"2151_CR7","doi-asserted-by":"publisher","first-page":"S1324","DOI":"10.1016\/j.annonc.2023.10.085","volume":"34","author":"O Sartor","year":"2023","unstructured":"Sartor O, Castellano Gauna DE, Herrmann K et al (2023) LBA13 phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). Ann Oncol 34:S1324\u2013S1325","journal-title":"Ann Oncol"},{"key":"2151_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M et al (2024) [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 25:563\u2013571","journal-title":"Lancet Oncol"},{"key":"2151_CR9","unstructured":"U.S. FDA (2025) FDA expands Pluvicto\u2019s metastatic castration-resistant prostate cancer indication. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication"},{"key":"2151_CR10","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","volume":"63","author":"AM H\u00f6vels","year":"2008","unstructured":"H\u00f6vels AM, Heesakkers RAM, Adang EM et al (2008) The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 63:387\u2013395","journal-title":"Clin Radiol"},{"key":"2151_CR11","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","volume":"43","author":"G Shen","year":"2014","unstructured":"Shen G, Deng H, Hu S, Jia Z (2014) Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skelet Radiol 43:1503\u20131513","journal-title":"Skelet Radiol"},{"key":"2151_CR12","doi-asserted-by":"crossref","unstructured":"Chong B, Khor V, Hoo JX et al (2025) Pelvic lymph node management in prostate cancer: a narrative review. Prostate Int 13:128\u2013136","DOI":"10.1016\/j.prnil.2025.02.001"},{"key":"2151_CR13","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jmir.2023.12.008","volume":"55","author":"KB Singh","year":"2024","unstructured":"Singh KB, London KI, Wong VCK, Mansberg R (2024) Diagnostic accuracy of bone scan at different PSA levels in biochemical recurrence of prostate cancer. J Med Imaging Radiat Sci 55:91\u201396","journal-title":"J Med Imaging Radiat Sci"},{"key":"2151_CR14","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395:1208\u20131216","journal-title":"Lancet"},{"key":"2151_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-022-00127-4","volume":"6","author":"N Regula","year":"2022","unstructured":"Regula N, Kostaras V, Johansson S et al (2022) Comparison of 68Ga-PSMA PET\/CT with fluoride PET\/CT for detection of bone metastatic disease in prostate cancer. Eur J Hybrid Imaging 6:5","journal-title":"Eur J Hybrid Imaging"},{"key":"2151_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.semnuclmed.2023.07.001","volume":"54","author":"MR Jochumsen","year":"2024","unstructured":"Jochumsen MR, Bouchelouche K (2024) PSMA PET\/CT for primary staging of prostate cancer\u2014an updated overview. Semin Nucl Med 54:39\u201345","journal-title":"Semin Nucl Med"},{"key":"2151_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41585-022-00618-w","volume":"19","author":"Y Wang","year":"2022","unstructured":"Wang Y, Galante JR, Haroon A et al (2022) The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. Nat Rev Urol 19:475\u2013493","journal-title":"Nat Rev Urol"},{"key":"2151_CR18","doi-asserted-by":"crossref","unstructured":"Widjaja L, Werner RA, Ross TL, Bengel FM, Derlin T (2021) PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under 177Lu-PSMA-617 radioligand therapy. Cancers (Basel) 13:29358","DOI":"10.3390\/cancers13122938"},{"key":"2151_CR19","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.121.262552","volume":"63","author":"S Pathmanandavel","year":"2022","unstructured":"Pathmanandavel S, Crumbaker M, Yam AO et al (2022) 177Lu-PSMA-617 and idronoxil in men with end-stage metastatic castration-resistant prostate cancer (LuPIN): patient outcomes and predictors of treatment response in a phase I\/II trial. J Nucl Med 63:560\u2013566","journal-title":"J Nucl Med"},{"key":"2151_CR20","doi-asserted-by":"crossref","unstructured":"Swiha M, Papa N, Sabahi Z et al (2024) Development of a visually calculated SUVmean (HIT Score) on screening PSMA PET\/CT to predict treatment response to 177Lu-PSMA therapy: comparison with quantitative SUVmean and patient outcomes. J Nucl Med 65:904\u2013908","DOI":"10.2967\/jnumed.123.267014"},{"key":"2151_CR21","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.2967\/jnumed.122.265242","volume":"64","author":"M Hotta","year":"2023","unstructured":"Hotta M, Gafita A, Murthy V et al (2023) PSMA PET tumor\u2013to\u2013salivary gland ratio to predict response to [177Lu]PSMA radioligand therapy: an international multicenter retrospective study. J Nucl Med 64:1024\u20131029","journal-title":"J Nucl Med"},{"key":"2151_CR22","first-page":"1","volume":"23","author":"A Iravani","year":"2019","unstructured":"Iravani A, Violet J, Azad A, Hofman M (2019) Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis 23:1\u201315","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2151_CR23","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2967\/jnumed.116.178228","volume":"58","author":"J Ferdinandus","year":"2017","unstructured":"Ferdinandus J, Eppard E, Gaertner FC, K\u00fcrpig S, Fimmers R, Yordanova A (2017) Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med 58:312\u2013319","journal-title":"J Nucl Med"},{"key":"2151_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s11307-024-01900-6","volume":"26","author":"R Eisazadeh","year":"2024","unstructured":"Eisazadeh R, Mirshahvalad SA, Schwieghofer-Zwink G, Hehenwarter L, Rendl G, Gampenrieder S (2024) Pre-treatment 68Ga-PSMA-11 PET\/CT prognostic value in predicting response to 177Lu-PSMA-I&T therapy and patient survival. Mol Imaging Biol 26:360\u2013369","journal-title":"Mol Imaging Biol"},{"key":"2151_CR25","doi-asserted-by":"crossref","unstructured":"Armstrong AJ, Sartor O, Bono J et al (2024) Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving [177Lu]Lu-PSMA-617 in the phase 3 VISION trial. Eur Urol 86:552\u2013562","DOI":"10.1016\/j.eururo.2024.08.021"},{"key":"2151_CR26","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP et al (2023) Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol 83:405\u2013412","journal-title":"Eur Urol"},{"key":"2151_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.euros.2023.08.007","volume":"57","author":"M Crumbaker","year":"2023","unstructured":"Crumbaker M, Goldstein LD, Murray DH, Tao J, Pathmanandavel S, Boulter N (2023) Circulating tumour DNA biomarkers associated with outcomes in metastatic prostate cancer treated with Lutetium-177-PSMA-617. Eur Urol Open Sci 57:30\u201336","journal-title":"Eur Urol Open Sci"},{"key":"2151_CR28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, Starzinski S, Kouchkovsky I, Koshkin V, Bose R, Chou J (2023) Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol 24:1266\u20131276","journal-title":"Lancet Oncol"},{"key":"2151_CR29","doi-asserted-by":"crossref","unstructured":"Sandhu S, Joshua AM, Emmett L et al (2022) PRINCE: phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 40:5017","DOI":"10.1200\/JCO.2022.40.16_suppl.5017"},{"key":"2151_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61961-z","volume":"14","author":"F Rosar","year":"2024","unstructured":"Rosar F, Burgard C, David S et al (2024) Dual FDG\/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT. Sci Rep 14:11271","journal-title":"Sci Rep"},{"key":"2151_CR31","doi-asserted-by":"crossref","unstructured":"Azad AA, Bressel M, Tan H et al (2024) Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol 25:1267\u20131276","DOI":"10.1016\/S1470-2045(24)00440-6"},{"key":"2151_CR32","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L et al (2022) PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol 23:1389\u20131397","journal-title":"Lancet Oncol"},{"key":"2151_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2967\/jnumed.124.268167","volume":"66","author":"RA Demirci","year":"2025","unstructured":"Demirci RA, Ghodsi A, Gulati R et al (2025) PET-based TheraP eligibility and outcomes of VISION-eligible patients with metastatic castration-resistant prostate cancer who received 177Lu-PSMA-617: importance of 18F-FDG-avid discordant findings. J Nucl Med 66:47\u201353","journal-title":"J Nucl Med"},{"key":"2151_CR34","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M et al (2023) Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 50:2830\u20132845","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR35","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.crad.2020.06.031","volume":"75","author":"RW Foley","year":"2020","unstructured":"Foley RW, Redman SL, Graham RN, Loughborough WW, Little D (2020) Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography\u2013computed tomography: normal patterns, pearls, and pitfalls. Clin Radiol 75:903\u2013913","journal-title":"Clin Radiol"},{"key":"2151_CR36","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","volume":"27","author":"S Huang","year":"2024","unstructured":"Huang S, Ong S, McKenzie D et al (2024) Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer\u2014a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 27:654\u2013664","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2151_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s11307-015-0866-0","volume":"17","author":"M Dietlein","year":"2015","unstructured":"Dietlein M, Kobe C, Kuhnert G et al (2015) Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol 17:575\u2013584","journal-title":"Mol Imaging Biol"},{"key":"2151_CR38","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40336-024-00631-6","volume":"12","author":"S Woo","year":"2024","unstructured":"Woo S, Freedman D, Becker AS et al (2024) Equivocal bone lesions on PSMA PET\/CT: systematic review and meta-analysis on their prevalence and malignancy rate. Clin Transl Imaging 12:485\u2013500","journal-title":"Clin Transl Imaging"},{"key":"2151_CR39","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1007\/s00259-024-06797-5","volume":"51","author":"A Rizzo","year":"2024","unstructured":"Rizzo A, Morbelli S, Albano D et al (2024) The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition. Eur J Nucl Med Mol Imaging 51:3753\u20133764","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12734-4","volume":"24","author":"Q Wang","year":"2024","unstructured":"Wang Q, Ketteler S, Bagheri S et al (2024) Diagnostic efficacy of [99mTc]Tc-PSMA SPECT\/CT for prostate cancer: a meta-analysis. BMC Cancer 24:982","journal-title":"BMC Cancer"},{"key":"2151_CR41","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/RLU.0000000000003410","volume":"46","author":"B Fallahi","year":"2021","unstructured":"Fallahi B, Khademi N, Karamzade-Ziarati N et al (2021) 99mTc-PSMA SPECT\/CT versus 68Ga-PSMA PET\/CT in the evaluation of metastatic prostate cancer. Clin Nucl Med 46:e68\u2013e74","journal-title":"Clin Nucl Med"},{"key":"2151_CR42","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/pros.24538","volume":"83","author":"I Duncan","year":"2023","unstructured":"Duncan I, Ingold N, Martinez-Marroquin E, Paterson C (2023) An Australian experience using Tc-PSMA SPECT\/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy. Prostate 83:970\u2013979","journal-title":"Prostate"},{"key":"2151_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1072437","volume":"12","author":"B Li","year":"2022","unstructured":"Li B, Duan L, Shi J et al (2022) Diagnostic performance of 99mTc-HYNIC-PSMA SPECT\/CT for biochemically recurrent prostate cancer after radical prostatectomy. Front Oncol 12:1072437","journal-title":"Front Oncol"},{"key":"2151_CR44","doi-asserted-by":"crossref","unstructured":"Kwan EM, Ng SWS, Tolmeijer SH et al (2025) Lutetium-177\u2013PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nat Med 31:2722\u20132736","DOI":"10.1038\/s41591-025-03704-9"},{"key":"2151_CR45","doi-asserted-by":"crossref","unstructured":"Ravi P, D\u2019Ipppolito A, Wurster J et al (2024) Determination of tumor PSMA expression and lutetium-PSMA response in men with prostate cancer using a novel epigenomic liquid biopsy platform. J Liq Biopsy 5:100193","DOI":"10.1016\/j.jlb.2024.100193"},{"key":"2151_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111774","volume":"181","author":"F Kleiburg","year":"2024","unstructured":"Kleiburg F, de Geus-Oei LF, Luelmo SAC et al (2024) PSMA PET\/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients. Eur J Radiol 181:111774","journal-title":"Eur J Radiol"},{"key":"2151_CR47","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, Eiber M (2018) Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics 38:200\u2013217","journal-title":"Radiographics"},{"key":"2151_CR48","doi-asserted-by":"publisher","first-page":"678","DOI":"10.2967\/jnumed.119.233817","volume":"61","author":"S Fanti","year":"2020","unstructured":"Fanti S, Hadaschik B, Herrmann K (2020) Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET\/CT imaging: the PSMA PET progression criteria. J Nucl Med 61:678\u2013682","journal-title":"J Nucl Med"},{"key":"2151_CR49","doi-asserted-by":"publisher","first-page":"e222148","DOI":"10.1148\/radiol.222148","volume":"308","author":"A Gafita","year":"2023","unstructured":"Gafita A, Djaileb L, Rauscher I et al (2023) Response evaluation criteria in PSMA PET\/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer. Radiology 308:e222148","journal-title":"Radiology"},{"key":"2151_CR50","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","volume":"48","author":"S Fanti","year":"2021","unstructured":"Fanti S, Goffin K, Hadaschik BA et al (2021) Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer. Eur J Nucl Med Mol Imaging 48:469\u2013476","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","volume":"5","author":"S Fanti","year":"2022","unstructured":"Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K (2022) EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography\/computed tomography in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy. Eur Urol Oncol 5:530\u2013536","journal-title":"Eur Urol Oncol"},{"key":"2151_CR52","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S\u2013150SS","journal-title":"J Nucl Med"},{"key":"2151_CR53","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1200\/JCO.2024.42.4_suppl.48","volume":"42","author":"CM Benitez","year":"2024","unstructured":"Benitez CM, Sahlstedt H, Brynolfsson J et al (2024) Updated automated PROMISE assessment: treatment response evaluation based on PSMA PET\/CT. J Clin Oncol 42:48","journal-title":"J Clin Oncol"},{"key":"2151_CR54","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","volume":"49","author":"F Rosar","year":"2022","unstructured":"Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA (2022) Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging 49:1584\u20131594","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR55","doi-asserted-by":"crossref","unstructured":"Heidegger I, Kesch C, Kretschmer A et al (2022) Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer\u2014a state of the art review. Ther Adv Med Oncol 14:17588359221081922","DOI":"10.1177\/17588359221081922"},{"key":"2151_CR56","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2967\/jnumed.122.265155","volume":"64","author":"V Murthy","year":"2023","unstructured":"Murthy V, Gafita A, Thin P et al (2023) Prognostic value of end-of-treatment PSMA PET\/CT in patients treated with 177Lu-PSMA radioligand therapy: a retrospective, single-center analysis. J Nucl Med 64:1737\u20131743","journal-title":"J Nucl Med"},{"key":"2151_CR57","first-page":"1651","volume":"63","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Weber M et al (2022) Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J Nucl Med 63:1651\u20131658","journal-title":"J Nucl Med"},{"key":"2151_CR58","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.2967\/jnumed.120.260836","volume":"62","author":"K Michalski","year":"2021","unstructured":"Michalski K, Klein C, Br\u00fcggemann T, Meyer PT, Jilg CA, Ruf J (2021) Assessing response to 177Lu-PSMA radioligand therapy using modified PSMA PET progression criteria. J Nucl Med 62:1741\u20131746","journal-title":"J Nucl Med"},{"key":"2151_CR59","doi-asserted-by":"crossref","unstructured":"Gafita A, Schroeder JA, Ceci F et al (2025) Treatment response evaluation in prostate cancer using PSMA PET\/CT. J Nucl Med 66:995\u20131004","DOI":"10.2967\/jnumed.124.268071"},{"key":"2151_CR60","doi-asserted-by":"crossref","unstructured":"Hotta M, Nguyen K, Thin P et al (2025) Kinetics of PSMA PET signal after radiotherapy in prostate cancer lesions: a single-center retrospective study. Radiother Oncol 207:110869","DOI":"10.1016\/j.radonc.2025.110869"},{"key":"2151_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1470-2045(25)00009-9","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett L, Subramaniam S, Crumbaker M et al (2025) Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol 26:291\u2013299","journal-title":"Lancet Oncol"},{"key":"2151_CR62","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2967\/jnumed.124.268325","volume":"66","author":"L Emmett","year":"2025","unstructured":"Emmett L (2025) SPECT deserves RESPECT: the potential of SPECT\/CT to optimize patient outcomes with theranostics therapy. J Nucl Med 66:349\u2013350","journal-title":"J Nucl Med"},{"key":"2151_CR63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.2024.42.4_suppl.32","volume":"42","author":"H Song","year":"2024","unstructured":"Song H, Leonio MI, Ferri V et al (2024) Assessing the clinical utility of rapid post-therapy whole-body digital SPECT\/CT in evaluating early treatment response of 177Lu-PSMA-617 treatment. J Clin Oncol 42:32","journal-title":"J Clin Oncol"},{"key":"2151_CR64","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2967\/jnumed.125.269640","volume":"66","author":"R Kashyap","year":"2025","unstructured":"Kashyap R, Buteau JP, Bressel M et al (2025) Prognostic value of posttherapy SPECT\/CT for overall survival in patients undergoing [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: results from 3 clinical trials. J Nucl Med 66:1265\u20131270","journal-title":"J Nucl Med"},{"key":"2151_CR65","doi-asserted-by":"crossref","unstructured":"John N, Pathmanandavel S, Crumbaker M et al (2023) 177Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy. J Nucl Med 65:809","DOI":"10.2967\/jnumed.122.264677"},{"key":"2151_CR66","first-page":"1945","volume":"65","author":"RA Demirci","year":"2024","unstructured":"Demirci RA, Gulati R, Hawley JE et al (2024) SPECT\/CT in early response assessment of patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617. J Nucl Med Publ Soc Nucl Med 65:1945\u20131951","journal-title":"J Nucl Med Publ Soc Nucl Med"},{"key":"2151_CR67","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.2967\/jnumed.123.267208","volume":"65","author":"S Yadav","year":"2024","unstructured":"Yadav S, Jiang F, Kurkowska S et al (2024) Assessing response to PSMA radiopharmaceutical therapies with single SPECT imaging at 24\u2009h after injection. J Nucl Med 65:1064\u20131069","journal-title":"J Nucl Med"},{"key":"2151_CR68","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/jnumed.122.264398","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Ho B et al (2023) Evaluation of 177Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med 64:221\u2013226","journal-title":"J Nucl Med"},{"key":"2151_CR69","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/jnumed.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M et al (2023) 177Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy. J Nucl Med 64:410\u2013415","journal-title":"J Nucl Med"},{"key":"2151_CR70","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","volume":"51","author":"MC Neubauer","year":"2024","unstructured":"Neubauer MC, Nicolas GP, Bauman A et al (2024) Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study. Eur J Nucl Med Mol Imaging 51:1185\u20131193","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR71","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1002\/cncr.35438","volume":"130","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, de Bono J, Nagarajah J et al (2024) Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: analysis of the phase 3 VISION trial. Cancer 130:3426\u20133435","journal-title":"Cancer"},{"key":"2151_CR72","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM et al (2016) Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34:1402\u20131418","journal-title":"J Clin Oncol"},{"key":"2151_CR73","doi-asserted-by":"publisher","first-page":"e628","DOI":"10.1016\/j.clon.2023.07.009","volume":"35","author":"H Abdel-Aty","year":"2023","unstructured":"Abdel-Aty H, O\u2019Shea L, Amos C et al (2023) The STAMPEDE2 trial: a site survey of current patterns of care, access to imaging and treatment of metastatic prostate cancer. Clin Oncol 35:e628\u2013e635","journal-title":"Clin Oncol"},{"key":"2151_CR74","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.2967\/jnumed.123.265916","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Benz M, Jiang F et al (2023) Do bone scans overstage disease compared with PSMA PET at initial staging? An international multicenter retrospective study with masked independent readers. J Nucl Med 64:1744\u20131747","journal-title":"J Nucl Med"},{"key":"2151_CR75","doi-asserted-by":"publisher","first-page":"e2452971","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve A, Armstrong WR, Clark KJ et al (2025) PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw Open 8:e2452971","journal-title":"JAMA Netw Open"},{"key":"2151_CR76","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","volume":"46","author":"B Grubm\u00fcller","year":"2019","unstructured":"Grubm\u00fcller B, Senn D, Kramer G et al (2019) Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 46:1063\u20131072","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.122.264104","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Nguyen A et al (2023) The prognostic value of posttreatment 68Ga-PSMA-11 PET\/CT and 18F-FDG PET\/CT in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 and NOX66 in a phase I\/II trial (LuPIN). J Nucl Med 64:69\u201374","journal-title":"J Nucl Med"},{"key":"2151_CR78","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2024.42.16_suppl.5008","volume":"42","author":"JS De Bono","year":"2024","unstructured":"De Bono JS, Morris MJ, Sartor O et al (2024) Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore. J Clin Oncol 42:5008","journal-title":"J Clin Oncol"},{"key":"2151_CR79","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/cancers16030482","volume":"16","author":"T B\u00fcttner","year":"2024","unstructured":"B\u00fcttner T, Dietrich D, Zarbl R et al (2024) Feasibility of monitoring response to metastatic prostate cancer treatment with a methylation-based circulating tumor DNA approach. Cancers (Basel) 16:482","journal-title":"Cancers (Basel)"},{"key":"2151_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01445-0","volume":"21","author":"T Dillinger","year":"2022","unstructured":"Dillinger T, Sheibani-Tezerji R, Pulverer W et al (2022) Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies. Mol Cancer 21:7","journal-title":"Mol Cancer"},{"key":"2151_CR81","doi-asserted-by":"publisher","first-page":"5851","DOI":"10.1007\/s00330-023-09527-x","volume":"33","author":"C Qin","year":"2023","unstructured":"Qin C, Goldberg O, Kakar G et al (2023) MRI fat fraction imaging of nodal and bone metastases in prostate cancer. Eur Radiol 33:5851\u20135855","journal-title":"Eur Radiol"},{"key":"2151_CR82","doi-asserted-by":"crossref","unstructured":"Cattabriga A, Renzetti B, Galuppi F et al (2024) Multiparametric whole-body MRI: a game changer in metastatic prostate cancer. Cancers (Basel) 16:2531","DOI":"10.3390\/cancers16142531"},{"key":"2151_CR83","doi-asserted-by":"publisher","first-page":"e0153840","DOI":"10.1371\/journal.pone.0153840","volume":"11","author":"MD Blackledge","year":"2016","unstructured":"Blackledge MD, Tunariu N, Orton MR et al (2016) Inter- and intra-observer repeatability of quantitative whole-body, diffusion-weighted imaging (WBDWI) in metastatic bone disease. PLoS One 11:e0153840","journal-title":"PLoS One"},{"key":"2151_CR84","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40644-020-00350-x","volume":"20","author":"P Pricolo","year":"2020","unstructured":"Pricolo P, Ancona E, Summers P et al (2020) Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. Cancer Imaging 20:77","journal-title":"Cancer Imaging"},{"key":"2151_CR85","doi-asserted-by":"crossref","unstructured":"Oprea-Lager DE, Cysouw MCF, Boellaard R et al (2021) Bone metastases are measurable: the role of whole-body MRI and positron emission tomography. Front Oncol 11:772530","DOI":"10.3389\/fonc.2021.772530"},{"key":"2151_CR86","doi-asserted-by":"publisher","first-page":"112033","DOI":"10.1016\/j.ejrad.2025.112033","volume":"186","author":"SV Nieuwenhove","year":"2025","unstructured":"Nieuwenhove SV, Lhommel R, Pasoglou V et al (2025) Fast (< 30\u2009min) \u201cAll-in-One\u201d whole-body MRI for TNM staging in high-risk prostate cancer (PCa): feasibility and comparison to 68Ga-prostate specific membrane antigen (PSMA)-PET\/CT. Eur J Radiol 186:112033","journal-title":"Eur J Radiol"},{"key":"2151_CR87","doi-asserted-by":"crossref","unstructured":"Donners R, Yiin R, Blackledge M, Koh D (2021) Whole-body diffusion-weighted MRI of normal lymph nodes: prospective apparent diffusion coefficient histogram and nodal distribution analysis in a healthy cohort. Cancer Imaging 21:64","DOI":"10.1186\/s40644-021-00432-4"},{"key":"2151_CR88","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s00259-021-05296-1","volume":"48","author":"S Malaspina","year":"2021","unstructured":"Malaspina S, Anttinen M, Taimen P, Jambor I, Sandell M (2021) Prospective comparison of 18F-PSMA-1007 PET\/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer. Eur J Nucl Med Mol Imaging 48:2951\u20132959","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR89","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eururo.2016.05.033","volume":"71","author":"AR Padhani","year":"2017","unstructured":"Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis Reporting and Data System for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71:81\u201392","journal-title":"Eur Urol"},{"key":"2151_CR90","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1593\/neo.81328","volume":"11","author":"AR Padhani","year":"2009","unstructured":"Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11:102\u2013125","journal-title":"Neoplasia"},{"key":"2151_CR91","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.eururo.2024.02.016","volume":"86","author":"A Garcia-Ruiz","year":"2024","unstructured":"Garcia-Ruiz A, Macarro C, Zacchi F et al (2024) Whole-body magnetic resonance imaging as a treatment response biomarker in castration-resistant prostate cancer with bone metastases: the iPROMET clinical trial. Eur Urol 86:272\u2013274","journal-title":"Eur Urol"},{"key":"2151_CR92","doi-asserted-by":"publisher","first-page":"e91779","DOI":"10.1371\/journal.pone.0091779","volume":"9","author":"MD Blackledge","year":"2014","unstructured":"Blackledge MD, Collins DJ, Tunariu N et al (2014) Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study. PLoS One 9:e91779","journal-title":"PLoS One"},{"key":"2151_CR93","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","volume":"46","author":"LM Sawicki","year":"2019","unstructured":"Sawicki LM, Kirchner J, Buddensieck C et al (2019) Prospective comparison of whole-body MRI and 68Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 46:1542\u20131550","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR94","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-022-00489-9","volume":"22","author":"PA Glemser","year":"2022","unstructured":"Glemser PA, Rotkopf LT, Ziener CH et al (2022) Hybrid imaging with [68Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer. Cancer Imaging 22:53","journal-title":"Cancer Imaging"},{"key":"2151_CR95","unstructured":"Salem AE, Soares HP, Fine GC, Morton KA (2023) DOTATATE PET\/CT imaging in prostate cancer: incidental observations and potential future implications. Endocr Abstr 98:C33"},{"key":"2151_CR96","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.2967\/jnumed.124.268020","volume":"65","author":"F Pouliot","year":"2024","unstructured":"Pouliot F, Saad F, Rousseau E et al (2024) Intrapatient intermetastatic heterogeneity determined by triple-tracer PET imaging in mCRPC patients and correlation to survival: the 3TMPO cohort study. J Nucl Med 65:1710\u20131717","journal-title":"J Nucl Med"},{"key":"2151_CR97","first-page":"241300","volume":"65","author":"A Zamanian","year":"2024","unstructured":"Zamanian A, Rousseau E, Buteau F-A et al (2024) The tumor sink effect on PSMA-PET\/CT in metastatic prostate cancer and its implications for PSMA-RLT: insight from the 3TMPO study. J Nucl Med 65:241300","journal-title":"J Nucl Med"},{"key":"2151_CR98","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, Jackson P, Ferdinandus J et al (2019) Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med 60:517\u2013523","journal-title":"J Nucl Med"},{"key":"2151_CR99","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2967\/jnumed.123.265448","volume":"65","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Rahbar K, Eiber M et al (2024) Renal and multiorgan safety of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy. J Nucl Med 65:71\u201378","journal-title":"J Nucl Med"},{"key":"2151_CR100","doi-asserted-by":"crossref","unstructured":"Duong TT, De Sarno D, Fakir H et al (2025) A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET\/CT and Monte Carlo simulation. Front Oncol 15:1600821","DOI":"10.3389\/fonc.2025.1600821"},{"key":"2151_CR101","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.2967\/jnumed.122.264770","volume":"64","author":"M Straub","year":"2023","unstructured":"Straub M, Kupferschl\u00e4ger J, Higuita LMS et al (2023) Dual-time-point posttherapy 177Lu-PSMA-617 SPECT\/CT describes the uptake kinetics of mCRPC lesions and prognosticates patients\u2019 outcome. J Nucl Med 64:1431\u20131438","journal-title":"J Nucl Med"},{"key":"2151_CR102","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/mp.15444","volume":"49","author":"KM Kim","year":"2022","unstructured":"Kim KM, Lee MS, Suh MS et al (2022) Comparison of voxel S-value methods for personalized voxel-based dosimetry of 177Lu-DOTATATE. Med Phys 49:1888\u20131901","journal-title":"Med Phys"},{"key":"2151_CR103","doi-asserted-by":"crossref","unstructured":"Eifer M, Sutherland DEK, Goncalves I et al (2025) Therapy-related myeloid neoplasms after [177Lu]Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer: a case series. J Nucl Med 66:579\u2013584","DOI":"10.2967\/jnumed.124.268640"},{"key":"2151_CR104","doi-asserted-by":"crossref","unstructured":"Mapelli P, Ghezzo S, Samanes Gajate AM et al (2022) 68Ga-PSMA and 68Ga-DOTA-RM2 PET\/MRI in recurrent prostate cancer: diagnostic performance and association with clinical and histopathological data. Cancers (Basel) 14:334","DOI":"10.3390\/cancers14020334"},{"key":"2151_CR105","doi-asserted-by":"crossref","unstructured":"Roll W, Schindler P, Masthoff M et al (2021) Evaluation of 68Ga-PSMA-11 PET-MRI in patients with advanced prostate cancer receiving 177Lu-PSMA-617 therapy: a radiomics analysis. Cancers (Basel) 13:3849","DOI":"10.3390\/cancers13153849"},{"key":"2151_CR106","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.120.242057","volume":"61","author":"R Seifert","year":"2020","unstructured":"Seifert R, Herrmann K, Kleesiek J, Sch\u00e4fers M, Shah V, Xu Z (2020) Semiautomatically quantified tumor volume using 68Ga-PSMA-11 PET as a biomarker for survival in patients with advanced prostate cancer. J Nucl Med 61:1786\u20131792","journal-title":"J Nucl Med"},{"key":"2151_CR107","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1007\/s00259-023-06555-z","volume":"51","author":"E Jafari","year":"2024","unstructured":"Jafari E, Zarei A, Dadgar H, Keshavarz A, Manafi-Farid R, Rostami H (2024) A convolutional neural network-based system for fully automatic segmentation of whole-body [68Ga]Ga-PSMA PET images in prostate cancer. Eur J Nucl Med Mol Imaging 51:1476\u20131487","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR108","doi-asserted-by":"publisher","unstructured":"Emmett L, Zheng A, Jin C et al (2025) \u2018One button push\u2019 fully automated PSMA PET quantification: correlation with progression free and overall survival in patients undergoing [177Lu] Lu PSMA therapy for metastatic castrate resistant prostate cancer. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.5054","DOI":"10.1200\/JCO.2025.43.16_suppl.5054"},{"key":"2151_CR109","doi-asserted-by":"crossref","unstructured":"Hein SP, Schultheiss M, Gafita A et al (2025) AI lesion tracking in PET\/CT imaging: a proposal for a Siamese-based CNN pipeline applied to PSMA PET\/CT scans. Eur J Nucl Med Mol Imaging 53:429\u2013441","DOI":"10.1007\/s00259-025-07426-5"},{"key":"2151_CR110","first-page":"00480","volume":"S0360-3016","author":"E Yazdani","year":"2025","unstructured":"Yazdani E, Sadeghi M, Karamzade-Ziarati N et al (2025) Machine learning-based dose prediction in [177Lu]Lu-PSMA-617 therapy by integrating biomarkers and radiomic features from [68Ga]Ga-PSMA-11 positron emission tomography\/computed tomography. Int J Radiat Oncol Biol Phys S0360-3016:00480\u201300488","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2151_CR111","first-page":"252132","volume":"66","author":"H Dadgar","year":"2025","unstructured":"Dadgar H, Karimzadeh R, Sharifi S et al (2025) Predicting post-treatment outcomes of Lu-177 PSMA therapy using deep learning on pre-treatment Ga-68 PSMA PET images. J Nucl Med 66:252132","journal-title":"J Nucl Med"},{"key":"2151_CR112","doi-asserted-by":"crossref","unstructured":"Hammes J, T\u00e4ger P, Drzezga A (2018) EBONI: a tool for automated quantification of bone metastasis load in PSMA PET\/CT. J Nucl Med 59:1070\u20131075","DOI":"10.2967\/jnumed.117.203265"},{"key":"2151_CR113","doi-asserted-by":"crossref","unstructured":"Acar E, Leblebici A, Ellidokuz BE, Ba\u015fb\u0131nar Y, Kaya G (2019) Machine learning for differentiating metastatic and completely responded sclerotic bone lesion in prostate cancer: a retrospective radiomics study. Br J Radiol 92:20190286","DOI":"10.1259\/bjr.20190286"},{"key":"2151_CR114","doi-asserted-by":"crossref","unstructured":"Islam MZ, Spiro E, Yap P-T, Gorin MA, Rowe SP (2025) The potential of generative AI with prostate-specific membrane antigen (PSMA) PET\/CT: challenges and future directions. Med Rev 5:265\u2013276","DOI":"10.1515\/mr-2024-0086"},{"key":"2151_CR115","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1007\/s00259-022-05883-w","volume":"49","author":"S Xue","year":"2022","unstructured":"Xue S, Gafita A, Dong C et al (2022) Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with 177Lu-PSMA I&T therapy. Eur J Nucl Med Mol Imaging 49:4064\u20134072","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR116","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1002\/mp.17684","volume":"52","author":"Z Lu","year":"2025","unstructured":"Lu Z, Hu J, Chen G et al (2025) Automatic bone marrow segmentation for precise [177Lu]Lu\u2010PSMA\u2010617 dosimetry. Med Phys 52:3970\u20133980","journal-title":"Med Phys"},{"key":"2151_CR117","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.semnuclmed.2024.05.004","volume":"55","author":"C Sachpekidis","year":"2025","unstructured":"Sachpekidis C, Dimitrakopoulou-Strauss A (2025) Long axial field-of-view (LAFOV) PET\/CT in prostate cancer. Semin Nucl Med 55:67\u201375","journal-title":"Semin Nucl Med"},{"key":"2151_CR118","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1007\/s00259-024-07060-7","volume":"52","author":"D Kersting","year":"2025","unstructured":"Kersting D, Borys K, K\u00fcper A et al (2025) Staging of prostate cancer with ultra-fast PSMA-PET scans enhanced by AI. Eur J Nucl Med Mol Imaging 52:1658\u20131670","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2151_CR119","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.2967\/jnumed.123.266167","volume":"64","author":"O Sartor","year":"2023","unstructured":"Sartor O, Ledet E, Huang M et al (2023) Prediction of resistance to 177Lu-PSMA therapy by assessment of baseline circulating tumor DNA biomarkers. J Nucl Med 64:1721\u20131725","journal-title":"J Nucl Med"},{"key":"2151_CR120","doi-asserted-by":"crossref","unstructured":"Kluge K, Haberl D, Haug A et al (2025) Genomic instability is associated with response to [177Lu]Lu-PSMA-I&T radioligand therapy: an exploratory, preliminary liquid biopsy analysis. Eur J Nucl Med Mol Imaging 52:4151\u20134156","DOI":"10.1007\/s00259-025-07280-5"},{"key":"2151_CR121","doi-asserted-by":"publisher","first-page":"318","DOI":"10.3390\/ijms26010318","volume":"26","author":"M Pedrani","year":"2025","unstructured":"Pedrani M, Barizzi J, Salfi G et al (2025) The emerging predictive and prognostic role of aggressive-variant-associated tumor suppressor genes across prostate cancer stages. Int J Mol Sci 26:318","journal-title":"Int J Mol Sci"},{"key":"2151_CR122","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.euros.2023.05.008","volume":"53","author":"J Vanwelkenhuyzen","year":"2023","unstructured":"Vanwelkenhuyzen J, Van Bos E, Van Bruwaene S et al (2023) AR and PI3K genomic profiling of cell-free DNA can identify poor responders to Lutetium-177-PSMA among patients with metastatic castration-resistant prostate cancer. Eur Urol Open Sci 53:63\u201366","journal-title":"Eur Urol Open Sci"},{"key":"2151_CR123","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1158\/1538-7445.AM2024-3696","volume":"84","author":"JM Sperger","year":"2024","unstructured":"Sperger JM, Sharifi MN, Nunamaker L et al (2024) Abstract 3696: Liquid biopsy biomarker analysis during treatment with 177Lu-PSMA-617 in castrate resistant prostate cancer. Cancer Res 84:3696","journal-title":"Cancer Res"},{"key":"2151_CR124","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M (2021) Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol 22:1115\u20131125","journal-title":"Lancet Oncol"},{"key":"2151_CR125","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.euo.2024.03.009","volume":"8","author":"A Gafita","year":"2025","unstructured":"Gafita A, Martin AJ, Emmett L et al (2025) Validation of prognostic and predictive models for therapeutic response in patients treated with [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a post hoc analysis from a randomised, open-label, phase 2 trial. Eur Urol Oncol 8:21\u201328","journal-title":"Eur Urol Oncol"},{"key":"2151_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102862","volume":"77","author":"K Herrmann","year":"2024","unstructured":"Herrmann K, Gafita A, de Bono JS et al (2024) Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial. eClinicalMedicine 77:102862","journal-title":"eClinicalMedicine"},{"key":"2151_CR127","doi-asserted-by":"crossref","unstructured":"Moazemi S, Erle A, Khurshid Z et al (2021) Decision-support for treatment with 177Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET\/CT and clinical parameters. Ann Transl Med 9:818","DOI":"10.21037\/atm-20-6446"},{"key":"2151_CR128","doi-asserted-by":"crossref","unstructured":"Moazemi S, Essler M, Schultz T, Bundschuh RA (2021) Predicting treatment response in prostate cancer patients based on multimodal PET\/CT for clinical decision support. In: Proceedings of the 11th international workshop on multimodal learning for clinical decision support (ML-CDS 2021) held in conjunction with MICCAI 2021, Strasbourg, 1 October 2021. Springer, Berlin, pp 22\u201335","DOI":"10.1007\/978-3-030-89847-2_3"},{"key":"2151_CR129","doi-asserted-by":"crossref","unstructured":"Gong K, Magnier B, L\u2019hostis S et al (2024) Predicting response to [177Lu]Lu-PSMA therapy in mCRPC using machine learning. J Pers Med 14:1068","DOI":"10.3390\/jpm14111068"},{"key":"2151_CR130","doi-asserted-by":"crossref","unstructured":"Zormpas-Petridis K, Tunariu N, Curcean A et al (2021) Accelerating whole-body diffusion-weighted MRI with deep learning-based denoising image filters. Radiol Artif Intell 3:e200279","DOI":"10.1148\/ryai.2021200279"},{"key":"2151_CR131","doi-asserted-by":"publisher","first-page":"S970","DOI":"10.1016\/j.annonc.2024.08.1689","volume":"35","author":"MS Hofman","year":"2024","unstructured":"Hofman MS, Gafita A, Bressel M et al (2024) 1608P Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET\/CT for response evaluation: analysis from the PRINCE trial. Ann Oncol 35:S970","journal-title":"Ann Oncol"},{"key":"2151_CR132","doi-asserted-by":"publisher","unstructured":"Herrmann K, Walz J, MacLennan S et al (2025) SPARC: the standardised prostate-specific membrane antigen positron emission tomography\/computed tomography analysis and reporting consensus: a Delphi analysis. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.08.005","DOI":"10.1016\/j.eururo.2025.08.005"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-025-02151-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-025-02151-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-025-02151-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:04:31Z","timestamp":1768565071000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-025-02151-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1186\/s13244-025-02151-x","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The clinical image included in Fig.\u00a0\n                      \n                      is fully anonymised and was used with institutional approval. All patients undergoing Lu-177 PSMA therapy at our centre provide written consent permitting the use of anonymised images for research, audit, and publication purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"G.C. is a lecturer for Telix, Curium and a consultant for Telix, BlueEarth Diagnostics, and FullLife Technologies. The remaining authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}